The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and oncolytic virus vectors have recently been investigated extensively for cancer therapy. However, preclinical and clinical studies have revealed that the clinical application of these two agents is hampered either by their weak anticancer activity or by their possible systemic toxicity. Therefore, strategies to maximize their anticancer activity and minimize their systemic toxicity are essential to the success of these agents in the treatment of cancers. The goal of this proposal is to determine the efficacy and safety of a tumor-specific replication-competent (oncolytic) adenovector expressing the TRAIL gene for the treatment of cancer. The hypothesis to be tested is that integration of virotherapy and TRAIL gene therapy into a single agent will enhance its in vivo transduction efficiency and apoptosis-induction capacity and that an oncolytic adenovector expressing both the TRAIL and E1A genes from the human telomerase reverse transcriptase (hTERT) promoter will target both virotherapy and TRAIL gene therapy to cancer, destroying tumor tissue but sparing normal tissue. Our preliminary studies showed that incorporating the TRAIL gene into an oncolytic adenovector enhanced viral replication and oncolysis in cancer cells, whether they were susceptible or resistant to the TRAIL gene, both in vitro and in vivo, with minimal replication activity and cytotoxic effects in normal human fibroblasts. Intralesional administration of the TRAIL-expressing oncolytic adenovector eliminated all subcutaneous xenograft tumors established from a human non-small cell lung cancer cell line in nu/nu mice, resulting in long-term tumor-free survival. To further test the hypothesis, we will determine the optimal adenovector systems for the delivery of hTERT-TRAIL to human and syngeneic Syrian hamster tumors by evaluating the therapeutic and side effects of hTERT-TRAIL delivered by an E1-deleted vector, an oncolytic vector, and a fiber-modified oncolytic vector in vitro and in vivo. We will also determine whether an immune response triggered by an adenovector will have any effect on either antitumor activity or side effects. Finally, we will determine the antitumor activity of the TRAIL-expressing oncolytic vector in both human and Syrian hamster syngeneic metastatic models established in both immunocompromised and immunocompetent animals. Completing the proposed studies will allow us to determine the optimal methods for delivery of hTERT- TRAIL and develop strategies for the treatment of metastasis. The results of these preclinical studies will also provide a solid scientific basis for future integration of TRAIL therapy and oncolytic virotherapy and may lead to new therapeutic agents for cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA092487-08
Application #
8018480
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Muszynski, Karen
Project Start
2001-07-01
Project End
2013-01-31
Budget Start
2011-02-01
Budget End
2013-01-31
Support Year
8
Fiscal Year
2011
Total Cost
$305,116
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Xiaochun; Lin, Steven H; Fang, Bingliang et al. (2013) Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol 8:1484-91
He, Yong; Zhou, Zhen; Hofstetter, Wayne L et al. (2012) Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 7:e31087
Zhang, Xiaochun; Fang, Bingliang; Mohan, Radhe et al. (2012) Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother Oncol 105:250-7
Liu, Xiaoying; Guo, Wei; Wu, Shuhong et al. (2012) Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol 83:1456-64
Wu, Shuhong; Wang, Li; Guo, Wei et al. (2011) Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities. J Med Chem 54:2668-79
Dai, Bingbing; Meng, Jieru; Peyton, Michael et al. (2011) STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71:3658-68
Guo, Wei; Wei, Xiaoli; Wu, Shuhong et al. (2010) Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species. Eur J Pharmacol 649:51-8
Zhou, Yanbin; Hofstetter, Wayne L; He, Yong et al. (2010) KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther 9:507-13
Meng, Jieru; Fang, Bingliang; Liao, Yong et al. (2010) Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 5:e13026
Wei, Xiaoli; Guo, Wei; Wu, Shuhong et al. (2010) Oxidative stress in NSC-741909-induced apoptosis of cancer cells. J Transl Med 8:37

Showing the most recent 10 out of 53 publications